Get the Stockscreener App
8.1368
1.93%
-0.1632
Cybin Inc stock is traded at $8.1368, with a volume of 94,471.
It is down -1.93% in the last 24 hours and down -16.68% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$8.30
Open:
$8.23
24h Volume:
94,471
Relative Volume:
0.31
Market Cap:
$174.52M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-39.18
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
-10.45%
1M Performance:
-16.68%
6M Performance:
-18.95%
1Y Performance:
-38.41%
1-Day Range:
$8.10
$8.43
1-Week Range:
$7.8001
$9.16
52-Week Range:
$6.50
$19.85
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
8.11 | 174.52M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.25 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.41 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
616.37 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.03 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
267.79 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet - MSN
How to Take Advantage of moves in (CYBN) - Stock Traders Daily
Cybin (OTCMKTS:CLXPF) Stock Price Down 2.5%Should You Sell? - MarketBeat
Revolutionizing Mental Health Through Psychedelic Therapeutics | by Dr. Gleb Tsipursky | Feb, 2025 - DataDrivenInvestor
Cybin (NYSE:CYBN) Price Target Cut to $150.00 by Analysts at HC Wainwright - MarketBeat
Cybin (OTCMKTS:CYBN) Trading Up 1.2%Here's Why - MarketBeat
Canaccord cuts Cybin stock target to $73, maintains Buy rating - MSN
Cybin (NYSE:CYBN) Price Target Lowered to $73.00 at Canaccord Genuity Group - MarketBeat
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin stock price target cut to $150 at H.C. Wainwright By Investing.com - Investing.com Australia
Canaccord cuts Cybin stock target to $73, maintains Buy rating By Investing.com - Investing.com Nigeria
(CYBN) Investment Analysis - Stock Traders Daily
Cybin sees third-quarter loss on R&D costs, advances clinical programs - Green Market Report
Cybin Accelerates PARADIGM Program for Depression Treatment - TipRanks
Cybin's Depression Drug Shows Perfect Response Rate, Advances to Pivotal Phase 3 with C$136M War Chest - StockTitan
Upstart (UPST) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights - Business Wire
Trade thoughts for Gold futures - The Globe and Mail
Is Rigetti Computing a Millionaire-Maker Stock? - The Globe and Mail
HC Wainwright Forecasts Cybin's Q3 Earnings (NYSE:CYBN) - MarketBeat
What is HC Wainwright's Estimate for Cybin FY2029 Earnings? - MarketBeat
Cybin (OTCMKTS:CLXPF) Shares Up 1.9%What's Next? - MarketBeat
What is HC Wainwright's Forecast for Cybin FY2029 Earnings? - MarketBeat
How To Trade (CYBN) - Stock Traders Daily
HC Wainwright Issues Optimistic Estimate for Cybin Earnings - Defense World
Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade - Yahoo Finance
HC Wainwright Has Bearish Outlook for Cybin FY2029 Earnings - Defense World
H.C. Wainwright maintains $190 target on Cybin Inc. shares - MSN
H.C. Wainwright maintains $190 target on Cybin Inc. shares By Investing.com - Investing.com South Africa
HC Wainwright Reiterates "Buy" Rating for Cybin (NYSE:CYBN) - MarketBeat
Cybin (OTCMKTS:CYBN) Shares Up 1.8%Should You Buy? - MarketBeat
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
(CYBN) Trading Signals - Stock Traders Daily
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
0.86%
Cap:
|
Volume (24h):